The MiniMed Paradigm® REAL-Time Revel™ is made by Medtroncs and is available for sale in the United States. The system is designed to make the lives of diabetics easier by monitoring and delivering insulin automatically. This closed loop system can be thought of as an artificial pancreas. The system also predictively alerts the wearer of high or low glucose events so they can take early action if required.

The artificial pancreas has been around for a while, however its not been very reliable mostly due to algorithms which control them. The innovation of giving early warning of hypoglycemia, is a great relief for patients and simplifies the complexity of diabetes management with easy-to-use features.

When using Medtronic’s glucose sensors with Paradigm Revel Insulin Pumps, trend alerts can notify patients of rapid changes in glucose levels so that they can take immediate corrective or preventative action after confirming glucose levels with a fingerstick glucose measurement. Several new CGM features, including predictive and rate of change alerts, provide earlier warnings of potential glycemic excursions to help patients stay in their target range. According to recent internal study, the use of predictive alerts improved hypoglycemic event detection by 36% compared to the standard low glucose alert.¹ All alerts can be customized to suit a patient’s lifestyle, such as creating different settings to accommodate for exercise or to manage nocturnal hypoglycemia.

New features in the insulin pump enable patients to tailor insulin delivery to meet their personal needs. Patients who are sensitive to insulin, such as children with diabetes, now have the opportunity to deliver insulin in smaller increments (0.025 units per hour.) In addition, insulin-using type 2 patients, who are often more insulin resistant, can more tightly control their glucose levels using the new 1:1 carbohydrate ratio. The system also enables patients to set up missed meal bolus reminders.

"Recent clinical evidence clearly supports that insulin pump therapy combined with continuous glucose monitoring improves patients' A1C while reducing the relative risk of severe hypoglycemia," said William Tamborlane, M.D., professor of pediatrics and chief of pediatric endocrinology at Yale University School of Medicine. "Advances such as predictive alerts and smaller basal delivery rates can help physicians and patients customize therapy to meet individual needs. This ultimately simplifies some of the complexity of daily diabetes management."

There is a growing body of clinical evidence that continues to prove that the more often patients use Personal CGM, the greater average glucose control (A1C) they can achieve without increasing hypoglycemia, including the JDRF-Funded Studies and REAL TREND Study.^2,3 Today, insulin pumps are covered by nearly all commercial and government insurance programs in the United States, and nearly 90 percent of type 1 diabetes patients with commercial insurance coverage have access to CGM when medical criteria is met. Personal CGM is approved for use by people ages 7 and older in the United States.

Based on press release at http://wwwp.medtronic.com/Newsroom/NewsReleaseDetails.do?itemId=1268411129675&lang=en_US

Josh

Re:Artificial Pancreas - MiniMed Paradigm and REAL-Time Revel Apr 06 2010 10:43:10 I found this page on the medtronic website. www.medtronicdiabetes.com/products/insul...s/pathway/index.html It says The Paradigm Pathway Program lets existing, in warranty customers upgrade to our new MiniMed Paradigm Revel Insulin Pump model for an affordable fee, over the life of the warranty from your existing in warranty MiniMed Paradigm Insulin Pump

#257

Josh

Re:Artificial Pancreas - MiniMed Paradigm and REAL-Time Revel Apr 17 2010 12:35:39 Here's the link for the Medtronic India diabetes page. No cost info that I can see but I'm sure you can call them and get pointed in the right direction. www.medtronic.co.in/IN/health/diabetes/therapy_options.html

#284

More Smilies

Enter code here   Nickname:  Email:  Message: